Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.55 GBX | -6.06% | +26.53% | -76.87% |
Apr. 30 | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue | AN |
Apr. 30 | Transcript : Shield Therapeutics plc, 2023 Earnings Call, Apr 30, 2024 |
Sales 2023 * | 12.36M 15.51M | Sales 2024 * | 36.29M 45.52M | Capitalization | 12.12M 15.21M |
---|---|---|---|---|---|
Net income 2023 * | -27M -33.87M | Net income 2024 * | -10M -12.54M | EV / Sales 2023 * | 1.43 x |
Net Debt 2023 * | 5.55M 6.97M | Net Debt 2024 * | 20.61M 25.86M | EV / Sales 2024 * | 0.9 x |
P/E ratio 2023 * |
-0.39
x | P/E ratio 2024 * |
-0.75
x | Employees | 27 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 43.82% |
Latest transcript on Shield Therapeutics plc
1 day | -6.06% | ||
1 week | +26.53% | ||
Current month | +14.81% | ||
1 month | -22.50% | ||
3 months | -74.80% | ||
6 months | -74.59% | ||
Current year | -76.87% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Madison
CEO | Chief Executive Officer | 57 | 21-05-31 |
Santosh Shanbhag
DFI | Director of Finance/CFO | 47 | Jan. 15 |
David Childs
COO | Chief Operating Officer | - | 11-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 18-07-25 | |
Director/Board Member | 66 | 16-01-31 | |
Director/Board Member | 57 | 21-05-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.55 | -6.06% | 8,522,072 |
24-05-02 | 1.65 | -5.71% | 15,893,320 |
24-05-01 | 1.75 | +29.63% | 19,413,980 |
24-04-30 | 1.35 | 0.00% | 13,190,020 |
24-04-29 | 1.35 | 0.00% | 5,942,486 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-76.87% | 16.12M | |
-1.43% | 103B | |
+8.96% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.04% | 16.94B | |
+6.79% | 14.07B | |
+38.61% | 12.35B |
- Stock Market
- Equities
- STX Stock